Evidence map›Paper›PMID 32611218›Full record

ArticleDrug delivery2020

Sequential delivery of dual drugs with nanostructured lipid carriers for improving synergistic tumor treatment effect.

Man Xu, Guangmeng Li, Haoxiang Zhang, Xiaoming Chen, Yi Li, Qianming Yao, Maobin Xie

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Drug delivery, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.

0numbers the graph read from it
0cells of the map it votes in
25citing papers in PubMed
2.3field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

25 citing papers in PubMed, 50 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Review
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Man XuQingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.
Guangmeng LiDepartment of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
Haoxiang ZhangDepartment of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
Xiaoming ChenDepartment of Biomedical Engineering, School of Basic Medical Sciences, Guangzhou Medical University, Guangzhou, China.
Yi LiSchool of Materials, The University of Manchester, Manchester, UK.
Qianming YaoQingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.
Maobin XieQingyuan People's Hospital, The Sixth Affiliated Hospital of Guangzhou Medical University, Qingyuan, China.
Guangzhou Medical University · CNThird Affiliated Hospital of Guangzhou Medical University · CNUniversity of Manchester · GB

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

To improve synergistic anticancer efficacy and minimize the adverse effects of chemotherapeutic drugs, temozolomide (TMZ) and curcumin (CUR) co-loaded nanostructured lipid carriers (NLCs) were prepared by microemulsion in this study. And the physicochemical properties, drug release behavior, intracellular uptake efficiency,

Indexed as

Antineoplastic AgentsApoptosisBrain NeoplasmsCell Line, TumorChemistry, PharmaceuticalCurcuminDrug CarriersDrug CombinationsDrug LiberationGliomaHumansLipidsNanoparticlesParticle SizeS PhaseTemozolomideAntineoplastic AgentsCurcuminDrug CarriersDrug CombinationsLipidsTemozolomidecurcuminnanostructured lipid carrierssequential drug releasesynergistic treatmentTemozolomide

Identifiers

PMID32611218
PMCPMC8216445
OpenAlexW3039460881

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.